These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32905515)

  • 21. Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer.
    Wan X; Zheng X; Pang X; Zhang Z; Zhang Q
    Colloids Surf B Biointerfaces; 2015 Dec; 136():817-27. PubMed ID: 26539808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
    Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
    Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG
    Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
    Chen S; Zhu X; Qiao H; Ye M; Lai X; Yu S; Ding L; Wen A; Zhang J
    Tumour Biol; 2016 Feb; 37(2):2321-31. PubMed ID: 26369543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
    Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
    Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbon-Ion Beam Irradiation Alone or in Combination with Zoledronic acid Effectively Kills Osteosarcoma Cells.
    Kim EH; Kim MS; Takahashi A; Suzuki M; Vares G; Uzawa A; Fujimori A; Ohno T; Sai S
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32187978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions.
    Dong M; Luo H; Liu R; Zhang J; Yang Z; Wang D; Wang Y; Chen J; Ou Y; Zhang Q; Wang X
    J Cancer; 2024; 15(3):699-713. PubMed ID: 38213724
    [No Abstract]   [Full Text] [Related]  

  • 29. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
    Mu Y; Sun D
    Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
    BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of potential lethal damage repair and related gene expression after carbon-ion beam irradiation to human lung cancer grown in nude mice.
    Yashiro T; Koyama-Saegusa K; Imai T; Fujisawa T; Miyamoto T
    J Radiat Res; 2007 Sep; 48(5):377-83. PubMed ID: 17690534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
    Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH
    Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
    Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
    Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WAF1 accumulation by carbon-ion beam and alpha-particle irradiation in human glioblastoma cultured cells.
    Takahashi A; Ohnishi K; Tsuji K; Matsumoto H; Aoki H; Wang X; Tamamoto T; Yukawa O; Furusawa Y; Ejima Y; Tachibana A; Ohnishi T
    Int J Radiat Biol; 2000 Mar; 76(3):335-41. PubMed ID: 10757313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiation-induced ICAM-1 expression via TGF-β1 pathway on human umbilical vein endothelial cells; comparison between X-ray and carbon-ion beam irradiation.
    Kiyohara H; Ishizaki Y; Suzuki Y; Katoh H; Hamada N; Ohno T; Takahashi T; Kobayashi Y; Nakano T
    J Radiat Res; 2011; 52(3):287-92. PubMed ID: 21343678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.
    Kano M; Matsushita K; Rahmutulla B; Yamada S; Shimada H; Kubo S; Hiwasa T; Matsubara H; Nomura F
    Gene Ther; 2016 Jan; 23(1):50-6. PubMed ID: 26241176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.